EUVIMEDOpdag EUVIMED
Systematische Übersicht

Immune checkpoint inhibitor–associated capillary leak syndrome: A systematic review and a worldwide pharmacovigilance study

Jonathan Wong So iD, Fatma Bouibede, Annie-Pierre Jonville-Béra iD, François Maillot iD, François Barbier, Bérenger Largeau iD

Journal of Internal Medicine · 2023-07 · 294 (1) · 58-68

DOI: 10.1111/joim.13641 ↗

At a glance

Systematische Übersicht in Journal of Internal Medicine, published online on 2023-04-20. Written by Jonathan Wong So and 5 co-authors. Institution: CHR d'Orléans, Service de Médecine Interne, Orléans, France. Major MEDLINE topics: Capillary Leak Syndrome, Antineoplastic Agents, Immunological, Drug-Related Side Effects and Adverse Reactions. Cited 10 times so far (Crossref); 30 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Although a few case reports have shown that immune checkpoint inhibitors (ICIs) are potential inducers of capillary leak syndrome (CLS), an incidental finding cannot be ruled out. The aim of this study was to describe the clinical characteristics of ICI‐induced CLS through a systematic review and to assess a potential safety signal.

Methods

Medline/PubMed, Embase, and Reactions Weekly were screened, and a global disproportionality study was performed using the World Health Organization pharmacovigilance database through January 15, 2023. A signal of disproportionate reporting was defined as a Bayesian information component (IC) with a 95% credibility interval (CrI) lower boundary that exceeds 0.

Results

A total of 47 cases of ICI‐associated CLS were included, 14 from the systematic review (of 61 screened articles) and 33 from VigiBase (of 34,058,481 reports of adverse drug reactions). The median time to CLS onset from the start of ICI was 12 weeks (interquartile range 8–49, n = 24). A total of 57% (8/14) of patients experienced an immune‐related adverse event (irAE) before CLS. A fatal outcome was reported in 23% (7/31) of patients. A significant overreporting of CLS was found with ICIs compared with all other drugs (IC 2.4, 95% CrI from 1.8 to 2.8).

Conclusion

This study showed a significant signal of disproportionality reporting for ICI‐induced CLS, characterized by a long time to onset, and compared with the idiopathic form of the disease with a less abrupt onset and a less consistent hemoconcentration pattern.

Subjects

MeSH terms (MEDLINE)

Capillary Leak SyndromeAntineoplastic Agents, ImmunologicalDrug-Related Side Effects and Adverse ReactionsHumansImmune Checkpoint InhibitorsPharmacovigilanceBayes TheoremRetrospective Studies

Author keywords

capillary leak syndromeedemaimmune checkpoint inhibitorimmune-related adverse event

Substances

Immune Checkpoint InhibitorsAntineoplastic Agents, Immunological

Authors and institutions

  • CHR d'Orléans, Service de Médecine Interne, Orléans, France.
  • CHR d'Orléans, Service de Médecine-Intensive Réanimation, Orléans, France.
  • CHRU de Tours, Service de Pharmacosurveillance, Centre Régional de Pharmacovigilance Centre-Val de Loire, Tours, France.
  • CHRU de Tours, Service de Médecine Interne et Immunologie Clinique, Tours, France.

ORCID profiles: Jonathan Wong So, Annie-Pierre Jonville-Béra, François Maillot, Bérenger Largeau

Cite

APA

Wong So, J., Bouibede, F., Jonville-Béra, A. P., Maillot, F., Barbier, F., & Largeau, B. (2023). Immune checkpoint inhibitor–associated capillary leak syndrome: A systematic review and a worldwide pharmacovigilance study. Journal of Internal Medicine, 294(1), 58-68. https://doi.org/10.1111/joim.13641

Vancouver

Wong So J, Bouibede F, Jonville-Béra AP, Maillot F, Barbier F, Largeau B. Immune checkpoint inhibitor–associated capillary leak syndrome: A systematic review and a worldwide pharmacovigilance study. Journal of Internal Medicine. 2023;294(1):58-68. doi:10.1111/joim.13641

BibTeX
@article{WongSo2023,
  author = {Wong So, Jonathan and Bouibede, Fatma and Jonville-Béra, Annie-Pierre and Maillot, François and Barbier, François and Largeau, Bérenger},
  title = {Immune checkpoint inhibitor–associated capillary leak syndrome: A systematic review and a worldwide pharmacovigilance study},
  journal = {Journal of Internal Medicine},
  year = {2023},
  volume = {294},
  number = {1},
  pages = {58--68},
  doi = {10.1111/joim.13641}
}
Start for free →